Get the Stockscreener App
0.2774
3.34%
-0.0096
After Hours:
.27
-0.0074
-2.67%
Scienture Holdings Inc stock is traded at $0.2774, with a volume of 412.46K.
It is down -3.34% in the last 24 hours and down -32.87% over the past month.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.
See More
Previous Close:
$0.287
Open:
$0.2801
24h Volume:
412.46K
Relative Volume:
0.17
Market Cap:
$11.39M
Revenue:
$656.60K
Net Income/Loss:
$-16.79M
P/E Ratio:
-0.2582
EPS:
-1.0743
Net Cash Flow:
$-11.12M
1W Performance:
-11.52%
1M Performance:
-32.87%
6M Performance:
-39.51%
1Y Performance:
-66.67%
1-Day Range:
$0.2699
$0.2899
1-Week Range:
$0.2699
$0.349
52-Week Range:
$0.2382
$2.60
Scienture Holdings Inc Stock (SCNX) Company Profile
Name
Scienture Holdings Inc
Sector
Industry
Phone
(800) 261 0281
Address
20 AUSTIN BLVD., COMMACK
Compare SCNX vs HITI, PETS, MEDS, POM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SCNX
Scienture Holdings Inc
|
0.2774 | 11.39M | 656.60K | -16.79M | -11.12M | -1.0743 |
HITI
High Tide Inc
|
2.79 | 248.71M | 486.49M | -33.29M | 10.86M | -0.3627 |
PETS
Petmed Express Inc
|
1.53 | 33.17M | 179.02M | -57.29M | -33.01M | -2.7487 |
MEDS
Trxade Health Inc
|
3.11 | 9.94M | 7.15M | 4.03M | -11.33M | -5.40 |
POM
Pomdoctor Ltd Adr
|
1.04 | 9.64M | 0 | 0 | 0 | 0.00 |
Scienture Holdings Inc Stock (SCNX) Latest News
Scienture stock jumps 21% on REZENOPY commercial launch - scanx.trade
SCNX Looks 12.9% Overvalued on GF Value™ - GuruFocus
Premarket Movers: Gainers and Losers for Sept. 22, 2026 - ChartMill
Scienture secures distribution deal for naloxone nasal spray - Investing.com
A nasal spray for opioid overdoses is headed to 2,000 clinics - Stock Titan
Scienture Holdings Inc. (SCNX) Q2 2026 Earnings: EPS Loss Narrower Than Estimated Despite Absence of Reported RevenueDebt Analysis Report - careplusvn.com
SCNX Q2 2026 Earnings: Narrower-Than-Expected Loss Beats Consensus, but Shares SlipEarnings Momentum Score - careplusvn.com
Scienture Holdings (NASDAQ: SCNX) Releases Updated Investor Presentation for Upcoming Analyst Meetings - Kalkine Media
Scienture Holdings Updates Investor Presentation and Guidance - TipRanks
SCNX: Two new therapies launched in 2026 drive revenue growth and pipeline momentum - TradingView
SCNX: Two new therapies launched in 2026 drive revenue growth and pipeline expansion - TradingView
Scienture Holdings at H.C. Wainwright: growth through niche drugs By Investing.com - Investing.com UK
Stay updated with the stocks that are on the move in today's after-hours session. - ChartMill
SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026 - marketscreener.com
Enterprise value to revenue forward of Scienture Holdings, Inc. – NASDAQ:SCNX - TradingView
Scienture (SCNX) CFO shows no personal stake in company stock - stocktitan.net
Scienture Holdings CFO Eric Sherb files initial beneficial ownership statement - Bitget
SCNX Q2 2026 Earnings: Loss Narrower Than Expected as EPS Beats Estimates by 70.16%ROA Comparison - dars.gov.et
SCNX | Scienture Holdings, Inc. Common FinancialsRevenue Breakdown - quiverquant.com
Scienture (SCNX) Levels: Finishes 4.68% Down at $0.45 on the Day; Trading Range: Price Remains Between $0.43 Support and $0.47 Resistance in the Available RecordWyckoff Upthrust - vinanet.vn
Scienture (SCNX) Quarterly Results: Profit Per Share Surpasses Its Benchmark on the Day; Post-Report: Shares Fall 0.49% in the Latest SessionEarnings Growth Forecast - vinanet.vn
Scienture Q2 Revenue Surges 510% Sequentially on Commercial Product Growth - Minichart
Scienture Q2 Revenue Reaches $343,639 as Net Loss Narrows 58% - Quiver Quantitative
Scienture (SCNX) Quarterly Results: Profit Per Share Surpasses Its Benchmark on the Day; Post-Report - dars.gov.et
Scienture (SCNX) Q1 2026 Results: Profit Per Share Clears Its Benchmark in the Latest Session; Closing Reaction: Shares Rise 3.76% in Latest TradingOperating Income Trends - vinanet.vn
$Scienture Holdings (SCNX.US)$ LMAO. They give us a buy rating, but wont let us buy. - Moomoo
SCNX Q1 2026 Earnings: Loss Narrower Than Expected, Shares Rise 2.18%Earnings Analysis - vinanet.vn
SCNX Q1 2026 Earnings: Narrower Loss Beats Estimates, but Shares SlipEarnings Analysis - vinanet.vn
Scienture Holdings 2Q Loss/Shr 7c >SCNX - moomoo.com
Scienture Holdings Reports Q2 2026 Results, Launches REZENOPY™ and Narrows Losses - Quiver Quantitative
SCNX Q2'26 Earnings: EPS estimate is (0.09) USD - TradingView
Scienture Holdings Q2 Results: EPS beats estimate, sales miss - scanx.trade
Scienture Holdings: Q2 Earnings Snapshot - marketscreener.com
Scienture Holdings (SCNX) grows ARBLI revenue but remains loss-making in Q2 2026 - Stock Titan
SCIENTURE Launches REZENOPY as Second FDA-Approved Commercial Product - Yahoo Finance
Scienture launches naloxone nasal spray for opioid overdose By Investing.com - Investing.com Nigeria
Scienture launches naloxone nasal spray for opioid overdose - Investing.com
SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray - marketscreener.com
Scienture Holdings Announces Commercial Launch and Fulfillment of Initial Purchase Orders of Rezenopy Nasal Spray 10 Mg - marketscreener.com
EXCLUSIVE: Scienture Launches Highest-Dose Naloxone Nasal Spray Rezenopy in US - Yahoo Finance
Scienture Holdings Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
Scienture Holdings Inc (SCNX) Stock News Today - TradingKey
Scienture Holdings Inc (SCNX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
SCNX Q1 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates by 64.35%Estimate Revision Count - dars.gov.et
Scienture Holdings (SCNX) Holds Near $0.38 as Trading Range Tightens Between $0.36 Support and $0.40 ResistanceComposite Profile - dars.gov.et
Scienture Holdings, Inc. (NASDAQ: SCNX) Stock Price, News & Analysis - Kalkine
SCNX Q1 2026 Earnings: Narrower Loss Beats Estimates, But Shares Slide 4%One-Time Gain Impact - careplusvn.com
Scienture Holdings, Inc. Revenue Breakdown – NASDAQ:SCNX - TradingView
Scienture Holdings Inc (SCNX) Cash Flow - TradingKey
Scienture Holdings Inc (SCNX) Valuation: PE, PB & Fair Value Analysis - tradingkey.com
When Will Scienture Holdings, Inc. (NASDAQ:SCNX) Become Profitable? - simplywall.st
Scienture Holdings Inc Stock (SCNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
11.14%
7.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):